Effects of Methylprednisolone on Ventilator-Free Days in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome and COVID-19: A Retrospective Study

Mohamed Badr, Bruno De Oliveira, Khaled Abdallah, Nadeem Ashraf, Yeldho Varghese, Dnyaseshwar Munde, Shameen Salam, Baraa Abduljawad, Khaled Saleh, Hussam Elkambergy, Ahmed Taha, Ahmed Bayrlee, Ali S. Wahla, Jamil Dibu, Rehan Haque, Fadi Hamed, Nadeem Rahman, Jihad MallatJournal of Clinical Medicine 2021 · DOI

TL;DR

This retrospective study found that methylprednisolone treatment in mechanically ventilated COVID-19 patients with ARDS was independently associated with more days free from the ventilator and a shorter hospital stay. While not impacting mortality, this suggests a potential benefit for this widely available corticosteroid in managing severe COVID-19.

What Problem Does This Paper Address?

The COVID-19 pandemic led to a surge in patients developing severe respiratory illness, specifically Acute Respiratory Distress Syndrome (ARDS), often requiring mechanical ventilation. The optimal treatment for these critically ill patients, especially regarding the use of corticosteroids, remained an area of active investigation. While some studies suggested benefits of corticosteroids like dexamethasone in reducing mortality, data on other steroids, particularly methylprednisolone, in mechanically ventilated COVID-19 patients were limited. This paper aimed to fill this gap by investigating whether methylprednisolone administration could improve outcomes, specifically by increasing the number of days patients were alive and free from mechanical ventilation (ventilator-free days or VFDs).

Methods

The researchers conducted a retrospective, single-center study at an intensive care unit. They analyzed data from 77 adult patients who had ARDS due to COVID-19 and required invasive mechanical ventilation between March and May 2020. The primary outcome was the number of ventilator-free days (VFDs) within the first 28 days of ICU admission. VFDs were defined as days alive and not requiring mechanical ventilation for at least 48 consecutive hours. To account for the competing event of death before day 28, they used a competing-risks regression model based on the Fine and Gray proportional subhazards model. They also analyzed secondary outcomes like hospital mortality, ICU length of stay, and hospital length of stay. Safety outcomes included positive cultures (blood, sputum, urine) and hyperglycemia. Crucially, their multivariable analysis adjusted for numerous potential confounders, including ventilator settings, prone positioning, organ failure support, disease severity, and the use of other medications like tocilizumab.

Datasets

The study utilized data from 77 patients admitted to the intensive care unit at Cleveland Clinic Abu Dhabi between March 1st and May 29th, 2020, who met the inclusion criteria (COVID-19, ARDS, and mechanical ventilation). This constitutes the primary dataset for the study. No new benchmarks were introduced.

Key Insights and Ideas

  • Methylprednisolone as a Ventilator Weaning Aid: The most significant finding is that methylprednisolone appears to help patients get off the ventilator sooner. This is crucial because prolonged mechanical ventilation is associated with numerous complications and poorer outcomes.
  • Shorter Hospital Stays: Beyond just ventilator weaning, patients receiving methylprednisolone also spent less time in the hospital overall, suggesting a faster recovery trajectory.
  • The Tocilizumab Conundrum: A notable observation was the higher incidence of positive blood cultures in patients receiving methylprednisolone. However, this was strongly linked to the fact that a large majority of these patients also received tocilizumab, another immunosuppressive drug. This suggests that the combination of these treatments might increase infection risk, rather than methylprednisolone alone.
  • No Mortality Benefit (Directly): While VFDs and hospital stay improved, the study did not find a statistically significant difference in overall hospital mortality between the groups. This highlights that while the drug might improve recovery metrics, it doesn't necessarily translate to survival in this specific cohort.

Key Results

  • Ventilator-Free Days (VFDs): Patients who received methylprednisolone had a mean of 18.8 VFDs (95% CI, 16.6–20.9) compared to 14.2 VFDs (95% CI, 12.6–16.7) in the non-methylprednisolone group. This difference of 4.61 days (95% CI, 1.10–8.12, p = 0.001) was statistically significant.
  • Independent Association with VFDs: After adjusting for confounders in multivariable analysis, methylprednisolone remained independently associated with a higher number of VFDs (subhazards ratio: 0.10, 95% CI: 0.02–0.45, p = 0.003).
  • Hospital Length of Stay: The methylprednisolone group had a significantly shorter hospital length of stay (24 days [IQR: 15–41 days]) compared to the non-methylprednisolone group (37 days [IQR: 23–52 days], p = 0.046).
  • Hospital Mortality: No significant difference was observed in hospital mortality rates between the groups (31.2% vs. 28.9%, p = 0.82).
  • Positive Blood Cultures: The incidence of positive blood cultures was higher in the methylprednisolone group (37.5% vs. 17.8%, p = 0.052), but this was noted in the context of 81% of these patients also receiving tocilizumab.

Limitations and Future Work

The authors acknowledge several limitations:

  • Single-Center Retrospective Design: This limits the generalizability of the findings, as management and outcomes can vary between institutions.
  • Potential for Selection Bias and Residual Confounding: Despite multivariable adjustments, it's impossible to completely rule out biases or unmeasured confounders.
  • Tocilizumab Confounding: The high co-administration of tocilizumab makes it challenging to isolate the effect of methylprednisolone alone on infection rates. While methylprednisolone's effect on VFDs was shown to be independent, this co-treatment is a significant factor.
  • Small Sample Size: The study was not powered to detect significant differences in mortality.

Future work should focus on further trials to definitively evaluate the benefits and safety of methylprednisolone, particularly in moderate to severe COVID-19 ARDS. Investigating the optimal dose and duration of methylprednisolone treatment is also highlighted as an area needing further research.

Summary updated

Abstract

<i>Objectives:</i> There are limited data regarding the efficacy of methylprednisolone in patients with acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) requiring invasive mechanical ventilation. We aimed to determine whether methylprednisolone is associated with increases in the number of ventilator-free days (VFDs) among these patients. <i>Design:</i> Retrospective single-center study. <i>Setting:</i> Intensive care unit. <i>Patients:</i> All patients with ARDS due to confirmed SARS-CoV-2 infection and requiring invasive mechanical ventilation between 1 March and 29 May 2020 were included. <i>Interventions:</i> None. <i>Measurements and Main Results:</i> The primary outcome was ventilator-free days (VFDs) for the first 28 days. Defined as being alive and free from mechanical ventilation. The primary outcome was analyzed with competing-risks regression based on Fine and Gray's proportional sub hazards model. Death before day 28 was considered to be the competing event. A total of 77 patients met the inclusion criteria. Thirty-two patients (41.6%) received methylprednisolone. The median dose was 1 mg·kg<sup>-1</sup> (IQR: 1-1.3 mg·kg<sup>-1</sup>) and median duration for 5 days (IQR: 5-7 days). Patients who received methylprednisolone had a mean 18.8 VFDs (95% CI, 16.6-20.9) during the first 28 days vs. 14.2 VFDs (95% CI, 12.6-16.7) in patients who did not receive methylprednisolone (difference, 4.61, 95% CI, 1.10-8.12, <i>p</i> = 0.001). In the multivariable competing-risks regression analysis and after adjusting for potential confounders (ventilator settings, prone position, organ failure support, severity of the disease, tocilizumab, and inflammatory markers), methylprednisolone was independently associated with a higher number of VFDs (subhazards ratio: 0.10, 95% CI: 0.02-0.45, <i>p</i> = 0.003). Hospital mortality did not differ between the two groups (31.2% vs. 28.9%, <i>p</i> = 0.82). Hospital length of stay was significantly shorter in the methylprednisolone group (24 days [IQR: 15-41 days] vs. 37 days [IQR: 23-52 days], <i>p</i> = 0.046). The incidence of positive blood cultures was higher in patients who received methylprednisolone (37.5% vs. 17.8%, <i>p</i> = 0.052). However, 81% of patients who received methylprednisolone also received tocilizumab. The number of days with hyperglycemia was similar in the two groups. <i>Conclusions:</i> Methylprednisolone was independently associated with increased VFDs and shortened hospital length of stay. The combination of methylprednisolone and tocilizumab was associated with a higher rate of positive blood cultures. Further trials are needed to evaluate the benefits and safety of methylprednisolone in moderate or severe COVID-19 ARDS.
BibTeX
@article{badr2021effects,
  author = {Mohamed Badr and Bruno De Oliveira and Khaled Abdallah and Nadeem Ashraf and Yeldho Varghese and Dnyaseshwar Munde and Shameen Salam and Baraa Abduljawad and Khaled Saleh and Hussam Elkambergy and Ahmed Taha and Ahmed Bayrlee and Ali S. Wahla and Jamil Dibu and Rehan Haque and Fadi Hamed and Nadeem Rahman and Jihad Mallat},
  title = {{Effects of Methylprednisolone on Ventilator-Free Days in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome and COVID-19: A Retrospective Study}},
  journal = {Journal of Clinical Medicine},
  year = {2021},
  doi = {10.3390/jcm10040760},
}
Figure